Reverse Triple Negative Immune Resistant Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of
combined treatment (sodium cromoglicate or choline) with immune checkpoint inhibitor in mTNBC
(triple negative breast cancer) patients who progressed during previous immune checkpoint
inhibitors.